-
-
关键词:
- 原发性食管恶性黑色素瘤 /
- 免疫治疗 /
- 乳酸脱氢酶 /
- 联合治疗
-
作者贡献赵华新：临床资料收集及文章撰写杨森：提供病理图片及说明郭献灵：论文指导许青：文章修改及审核
-
![]()
图 1 患者食管肿瘤切除术后病理HE染色图片(HE×100)
Figure 1 Postoperative pathological HE staining pictures of patients esophageal tumor (HE×100)
![]()
图 2 患者食管肿瘤病理HE染色图片可见色素沉着(HE×400)
Figure 2 Pathological HE staining picture showed pigmentation (HE ×400)
-
[1] Matsutani T, Onda M, Miyashita M, et al. Primary malignant melanoma of the esophagus treated by esophagectomy and systemic chemotherapy[J]. Dis Esophagus, 2001, 14(3-4): 241-244. doi: 10.1046/j.1442-2050.2001.00193.x
[2] Sun H, Gong L, Zhao G, et al. Clinicopathological characteristics, staging classification, and survival outcomes of primary malignant melanoma of the esophagus[J]. J Surg Oncol, 2018, 117(4): 588-596. doi: 10.1002/jso.24905
[3] Weiner JP, Shao M, Schwartz D, et al. Patterns of care and survival outcomes in the treatment of esophageal melanoma[J]. Dis Esophagus, 2017, 30(2): 1-6. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=62132edd3c10a314610ed4aeb1b1b052
[4] Wang L, Zong L, Nakazato H, et al. Primary advanced esophago-gastric melanoma: A rare case[J]. World J Gastroenterol, 2016, 22(11): 3296-3301. doi: 10.3748/wjg.v22.i11.3296
[5] Ahn JY, Hwang HS, Park YS, et al. Endoscopic and Pathologic Findings Associated with Clinical Outcomes of Melanoma in the Upper Gastrointestinal Tract[J]. Ann Surg Oncol, 2014, 21(8): 2532-2539. doi: 10.1245/s10434-014-3637-2
[6] Cui C, Mao L, Chi Z, et al. A phase Ⅱ, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma[J]. Mol Ther, 2013, 21(7): 1456-1463. doi: 10.1038/mt.2013.79
[7] Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci, 2018, 109(4): 1207-1219. http://cn.bing.com/academic/profile?id=98b8cc4111b00f7466609e21395dad20&encoded=0&v=paper_preview&mkt=zh-cn
[8] Wang X, Kong Y, Chi Z, et al. Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients[J]. Thorac Cancer, 2019, 10(4): 950-956. http://cn.bing.com/academic/profile?id=623b87a3c41eabaa61910f1da11f8610&encoded=0&v=paper_preview&mkt=zh-cn
[9] Jun G, Sheng X, Si L, et al. A phase Ⅰb study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma[J]. J Clin Oncol, 2018, 36(15_suppl): 9528. doi: 10.1200/JCO.2018.36.15_suppl.9528
[10] D'Angelo SP, Larkin J, Sosman JA, et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis[J]. J Clin Oncol, 2017, 35(2): 226-235. doi: 10.1200/JCO.2016.67.9258
[11] Langer R, Becker K, Feith M, et al. Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases[J]. Mod Pathol, 2011, 24(4): 495-501. doi: 10.1038/modpathol.2010.220
下载:
计量
- 文章访问数: 1633
- HTML全文浏览量: 515
- PDF下载量: 419
